C12N 2820/60
From viruses
Official title: from viruses
C12N2820/60 (From viruses) appears on 72 US grants and 147 published applications in this corpus.
Search patents in C12N- Granted patents
- 72
- Published applications
- 147
- Assignees
- 83
- Inventors
- 300
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 1 | 2 |
| 2007 | 0 | 3 |
| 2008 | 1 | 4 |
| 2009 | 1 | 3 |
| 2010 | 3 | 3 |
| 2011 | 1 | 3 |
| 2012 | 1 | 2 |
| 2013 | 3 | 6 |
| 2014 | 4 | 6 |
| 2015 | 2 | 5 |
| 2016 | 4 | 4 |
| 2017 | 4 | 7 |
| 2018 | 1 | 6 |
| 2019 | 4 | 9 |
| 2020 | 4 | 10 |
| 2021 | 0 | 3 |
| 2022 | 2 | 14 |
| 2023 | 14 | 13 |
| 2024 | 10 | 12 |
| 2025 | 7 | 19 |
| 2026 | 2 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- DNA vectors and elements for sustained gene expression in eukaryotic cells28 Apr 2026US 12,612,646 B2Dna Twopointo Inc.
- Enabling cholesterol catabolism in mammalian cells lacking same10 Feb 2026US 12,545,918 B2University of South Alabama Foundation for Research and Commercialization
- Non-immunogenic circular, non-viral DNA vectors18 Nov 2025US 12,473,567 B2Rampart Bioscience, Inc.
- Non-immunogenic circular, non-viral DNA vectors18 Nov 2025US 12,473,568 B2Rampart Bioscience, Inc.
- Closed-ended DNA vectors obtainable from cell-free synthesis and process for obtaining ceDNA vectors14 Oct 2025US 12,442,015 B2Generation Bio Co.
- Artificial martellivirales satellite rnas1 Oct 2026US 2026/0297605 A1Flagship Pioneering Innovations Vii, LLC
- Function-enhanced engineered ebna1 for protein expression in mammalian cells27 Aug 2026US 2026/0250327 A1Wuxi Biologics Ireland Limited
- Components for genomic editing13 Aug 2026US 2026/0234657 A1Kano Therapeutics Inc.
- Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy2 Jul 2026US 2026/0183354 A2SunVax mRNA Therapeutics Inc.
- Optimized PAH gene and expression cassette and use thereof25 Jun 2026US 2026/0174901 A1Suzhou Nggt Biotechnology Co., Ltd.
Most cited
By later US patents
- RNA transformation vector79US 5,500,360 AMycogen Plant Science, Inc. · 1996
- Immunisation of large mammals with low doses of RNA62US 10,487,332 B2Glaxosmithkline Biologicals SA · 2019
- Alphavirus replicons and helper constructs58US 7,442,381 B2AlphaVax, Inc. · 2008
- Methods for the production of iPS cells using non-viral approach45US 8,546,140 B2Cellular Dynamics International, Inc. · 2013
- Restrictive inverted terminal repeats for viral vectors38US 9,169,494 B2The University of North Carolina at Chapel Hill · 2015